Enterprise Value

1.857B

Cash

92.15M

Avg Qtr Burn

N/A

Short % of Float

16.02%

Insider Ownership

2.08%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Linzess® (linaclotide) Details
Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder

Approved

Quarterly sales

Approved

Quarterly sales

Phase 3

Data readout

Phase 2

Data readout

IW-3300 Details
Endometriosis, Interstitial cystitis/bladder pain syndrome, Visceral pain

Phase 2

Data readout

Apraglutide (agonist of the GLP-2 receptor) Details
Short bowel syndrome, Short bowel syndrome with colon-in-continuity

Phase 2

Update

CNP-104 Details
Autoimmune disease, Primary biliary cholangitis, Liver disease

Phase 2a

Data readout

Linaclotide Details
Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder, Constipation

Failed

Discontinued